Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic imm… Read more
Kaleido Biosciences Inc (KLDO) - Total Liabilities
Latest total liabilities as of March 2022: $39.53 Million USD
Based on the latest financial reports, Kaleido Biosciences Inc (KLDO) has total liabilities worth $39.53 Million USD as of March 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kaleido Biosciences Inc - Total Liabilities Trend (2016–2021)
This chart illustrates how Kaleido Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kaleido Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Kaleido Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CN MINSHENG BK -H-
MU:GHFH
|
Germany | €7.05 Trillion |
|
Supalai PCL
STU:NYVL
|
Germany | €44.50 Billion |
|
NB Distressed Debt Investment Fund Ltd
LSE:NBDD
|
UK | $2.75 Million |
|
CHANGAN MINSHENG-H-
BE:W8R
|
Germany | €2.98 Billion |
Liability Composition Analysis (2016–2021)
This chart breaks down Kaleido Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kaleido Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kaleido Biosciences Inc (2016–2021)
The table below shows the annual total liabilities of Kaleido Biosciences Inc from 2016 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-12-31 | $39.53 Million | +1.76% |
| 2020-12-31 | $38.85 Million | +16.23% |
| 2019-12-31 | $33.42 Million | +23.20% |
| 2018-12-31 | $27.13 Million | -63.55% |
| 2017-12-31 | $74.43 Million | +239.75% |
| 2016-12-31 | $21.91 Million | -- |